FierceBiotech 2026-02-23 UPDATED: FDA illuminates new approval pathway for bespoke gene editing therapies
FierceBiotech 2026-02-23 iRegene Hits Dual Global Firsts: U.S. Patient Dosed in Phase IIa for NouvNeu001 in Parkinson’s and First Enrollment in China’s Randomized MSA Trial for NouvNeu004
FierceBiotech 2026-02-20 Grail stock craters as key NHS-Galleri cancer blood test trial fails to hit primary endpoint
FierceBiotech 2026-02-20 Candel glows brighter with $100M RTW royalty deal to fund prostate cancer drug's launch
FierceBiotech 2026-02-19 Sanofi backs Altesa's $75M series B to bankroll antiviral's midstage rhinovirus study